đź“Š Evidence-Based Reference
iplan rt dose
Brainlab Ag
Summary: iPlan RT Dose is a treatment planning system by Brainlab Ag, primarily used for stereotactic radiosurgery. Key evidence highlights its application in treating brain metastases and lung cancer with precise dose delivery.
FDA Clearance Information
Pathway
510K
Number
K053584 ↗
Decision Date
July 12, 2006
Product Code
MUJ
Device Class
Class 2
Evidence
0 studies
The iPlan RT Dose by Brainlab Ag was cleared via the FDA 510(k) pathway on July 12, 2006. It is classified as a Class 2 device under product code MUJ.
What It Is
The iPlan RT Dose is a sophisticated treatment planning system designed for stereotactic radiosurgery. It facilitates precise dose calculations and delivery for complex cases, such as brain metastases and lung cancer.
Clinical Applications
Commonly used in the treatment of multiple brain metastases and lung cancer, the iPlan RT Dose supports clinicians in planning and executing stereotactic radiosurgery with high precision.
Evidence Summary
The literature includes four studies, ranging from 2011 to 2022, encompassing various study types. These studies explore the device's application in stereotactic radiosurgery and its dosimetric accuracy.
Reported Outcomes
Published studies report that the iPlan RT Dose effectively supports the treatment of multiple brain metastases and lung cancer by enabling precise dose delivery. The system's ability to integrate volumetric modulated arc therapy (VMAT) and dynamic conformal arc therapy (DCAT) enhances treatment accuracy.
Safety Profile
Reported complications include potential dose attenuation and perturbation due to the carbon fiber couch top used in conjunction with the device. No direct adverse events related to the device's core functionality were noted in the studies.
Evidence Limitations
The evidence is limited by the small number of studies and the lack of large-scale randomized controlled trials. Further research is needed to explore long-term outcomes and safety in diverse patient populations.
Frequently Asked Questions
What are the clinical indications for iplan rt dose?
The iPlan RT Dose is indicated for use in stereotactic radiosurgery, particularly for treating brain metastases and lung cancer.
What outcomes have been reported in clinical studies?
Studies have reported effective dose delivery and treatment accuracy in managing brain metastases and lung cancer.
What complications have been reported?
Safety data indicate potential dose attenuation due to the carbon fiber couch top, but no direct adverse events related to the device itself.
Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference.
It does not constitute medical advice, product endorsement, or a recommendation for clinical use.
Always consult manufacturer documentation and clinical judgment for patient care decisions.